Last reviewed · How we verify

fixed combination latanoprost-timolol

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 3 active Small molecule

fixed combination latanoprost-timolol is a Prostaglandin analog and beta-blocker combination Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.

Latanoprost-timolol is a fixed combination of a prostaglandin analog and a beta-blocker that works by reducing intraocular pressure in the eye.

Latanoprost-timolol is a fixed combination of a prostaglandin analog and a beta-blocker that works by reducing intraocular pressure in the eye. Used for Glaucoma, Ocular hypertension.

At a glance

Generic namefixed combination latanoprost-timolol
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug classProstaglandin analog and beta-blocker combination
TargetBeta-adrenergic receptors, Prostaglandin receptors
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Latanoprost is a prostaglandin analog that increases the outflow of aqueous humor from the eye, while timolol is a beta-blocker that decreases the production of aqueous humor. This combination reduces intraocular pressure in patients with glaucoma or ocular hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about fixed combination latanoprost-timolol

What is fixed combination latanoprost-timolol?

fixed combination latanoprost-timolol is a Prostaglandin analog and beta-blocker combination drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., indicated for Glaucoma, Ocular hypertension.

How does fixed combination latanoprost-timolol work?

Latanoprost-timolol is a fixed combination of a prostaglandin analog and a beta-blocker that works by reducing intraocular pressure in the eye.

What is fixed combination latanoprost-timolol used for?

fixed combination latanoprost-timolol is indicated for Glaucoma, Ocular hypertension.

Who makes fixed combination latanoprost-timolol?

fixed combination latanoprost-timolol is developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (see full Pfizer's Upjohn has merged with Mylan to form Viatris Inc. pipeline at /company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc).

What drug class is fixed combination latanoprost-timolol in?

fixed combination latanoprost-timolol belongs to the Prostaglandin analog and beta-blocker combination class. See all Prostaglandin analog and beta-blocker combination drugs at /class/prostaglandin-analog-and-beta-blocker-combination.

What development phase is fixed combination latanoprost-timolol in?

fixed combination latanoprost-timolol is in Phase 3.

What are the side effects of fixed combination latanoprost-timolol?

Common side effects of fixed combination latanoprost-timolol include Eye irritation, Headache, Dizziness.

What does fixed combination latanoprost-timolol target?

fixed combination latanoprost-timolol targets Beta-adrenergic receptors, Prostaglandin receptors and is a Prostaglandin analog and beta-blocker combination.

Related